In 2004, circulating tumor cells (CTC) enumeration by the CellSearch® technique at baseline
and during treatment was reported to be associated with prognosis in metastatic breast …

Background We conducted a meta-analysis in nonmetastatic breast cancer patients treated
by neoadjuvant chemotherapy (NCT) to assess the clinical validity of circulating tumor cell (…

Background The heterogeneity of metastatic breast cancer (MBC) necessitates novel
biomarkers allowing stratification of patients for treatment selection and drug development. We …

Background Among breast cancers without human epidermal growth factor receptor 2 (HER2)
amplification, overexpression, or both, a large proportion express low levels of HER2 that …

Background The recurrence score based on the 21-gene breast-cancer assay has been
clinically useful in predicting a chemotherapy benefit in hormone-receptor–positive, human …

Background The 70-gene signature test (MammaPrint) has been shown to improve
prediction of clinical outcome in women with early-stage breast cancer. We sought to provide …

Background We assessed the prognostic significance of the presence of micrometastasis in
the bone marrow at the time of diagnosis of breast cancer by means of a pooled analysis. …

Background We aimed to assess the clinical validity of circulating tumour cell (CTC) quantification
for prognostication of patients with metastatic breast cancer by undertaking a pooled …

Background Brain metastases occur in 30–50% of patients with metastatic HER2-positive
breast cancer. In the case of diffuse brain metastases, treatment is based on whole brain …

Background Since 2005, 12 months of adjuvant trastuzumab has been the standard treatment
for patients with HER2-positive early-stage breast cancer. However, the optimum duration …